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Biosimilar insulins: guidance for data interpretation by clinicians
and users
L. Heinemann1, P. D. Home2 & M. Hompesch3
1Science & Co, Düsseldorf, Germany
2Institute of Cellular Medicine - Diabetes, The Medical School, Newcastle University, Newcastle upon Tyne, UK
3Profil Institute for Clinical Research, San Diego, CA, USA
Biosimilar insulins are approved copies of insulins outside patent protection. Advantages may include greater market competition and potential cost
reduction, but clinicians and users lack a clear perspective on ‘biosimilarity’ for insulins. The manufacturing processes for biosimilar insulins are
manufacturer-specific and, although these are reviewed by regulators there are few public data available to allow independent assessment or review
of issues such as intrinsic quality or batch-to-batch variation. Preclinical measures used to assess biosimilarity, such as tissue and cellular studies of
metabolic activity, physico-chemical stability and animal studies of pharmacodynamics, pharmacokinetics and immunogenicity may be insufficiently
sensitive to differences, and are often not formally published. Pharmacokinetic and pharmacodynamic studies (glucose clamps) with humans, although
core assessments, have problems of precision which are relevant for accurate insulin dosing. Studies that assess clinical efficacy and safety and device
compatibility are limited by current outcome measures, such as glycated haemoblobin levels and hypoglycaemia, which are insensitive to differences
between insulins. To address these issues, we suggest that all comparative data are put in the public domain, and that systematic clinical studies are
performed to address batch-to-batch variability, delivery devices, interchangeability in practice and long-term efficacy and safety. Despite these challenges
biosimilar insulins are a welcome addition to diabetes therapy and, with a transparent approach, should provide useful benefit to insulin users.
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Introduction and Background
The first ‘biosimilar’ insulin [Eli Lilly and Boehringer Ingel-
heim’s insulin glargine with the trade name Abasaglar in the
European Union (EU) and Basaglar in the USA] has recently
received market approval by the regulatory authorities in
Europe [1]. In the USA it has received tentative approval but
not as a biosimilar, as that regulatory pathway does not yet
exist for insulins. Patents for insulin glargine are soon to expire
(in mid-2015), and copies of insulin glargine made by other
pharmaceutical companies are already marketed in India,
China, Mexico and other countries. Merck, Biocon (Mylan)
and Sanofi are known to be developing biosimilar insulins
(glargine and lispro) for highly regulated markets, so it seems
likely that several biosimilar insulins will come to market
in the next 5 years. The documents issued by the European
Medicines Agency (EMA) for Abasaglar, however, highlight the
stringency with which the regulatory authorities will evaluate
a market approval dossier for a prospective biosimilar insulin,
and detail some of the issues that can arise [2].
Clinicians considering the use of biosimilar insulins as
efficacious and safe options for people with diabetes require an
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understanding of these products from regulatory, manufactur-
ing and clinical points of view. Even if clinicians are forced into
use of such products by payers and funders, there will be a need
for them (and others involved in the selection of insulins for
clinical use) to understand the clinical issues biosimilar insulins
might present. This is particularly pertinent where choice of
insulin formulation usedmight be determined by a pharmacist.
The aim of the present review was to assist clinician
decision-making by discussing aspects of these products that
may be relevant to clinical practice. To illustrate this (Table 1),
the information available in the public domain is summarized
in the context of current approval pathways in more highly
regulated markets. A more detailed summary of global regula-
tory requirements is published elsewhere [3].
Reasons for the Development
of Biosimilar Insulins
Biosimilars are approved copies of already marketed biolog-
ical medicines. Accordingly, they provide an alternative to
existing biological medicines that have lost patent protection
[4]. Biosimilars in other areas of medicine are usually offered
for a lower price than the original molecules, and specula-
tion is that price reductions of up to 50% might eventually be
expected [5,6]. Enhanced competition is welcome, and keener
market pricing may improve access to such medicines. For
payers, reimbursing biosimilar medicines has the potential to
drive down costs through substitution and/or constraints on
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Table 1. What does the clinician and the user need to know about a biosimilar insulin?
Domain Required knowledge and information Comment
Manufacturing
process quality
Appropriate processes to define quality and
their limitations; appropriate components,
consumables and ability
No information in public domain – regarded as commercial secrets;
regulators act as the consumer watchdog but are not monitored
themselves; company reputation often used as default
Batch-to batch
variability
Monitoring processes in place; results of such
processes
No information in public domain; regulatory monitoring probably
inadequate; independent studies possible on marketed materials
Toxicological
considerations
Regulators performed due diligence and
satisfied for both biosimilar and original
insulin
Studies difficult with insulin, and need specific expert oversight;
detailed information rarely in public domain
Preclinical
comparability
Have cellular tests demonstrated comparable
receptor and cellular metabolic activity
and dynamics?
Some information in public domain (e.g. in EU EPAR for Lilly




Physicochemical stability data in more
extreme conditions (warm climates,
pumps); post-injection metabolism
Data assessed by regulators and not in public domain; no data on
metabolism of Lilly insulin glargine after subcutaneous injection;
independent studies possible on marketed products
Pharmacokinetic
comparability
Similarity of metrics such as time of onset,
peak and duration of profile, area under
concentration curve
Insulin assays not a simple area; confounding by endogenous
insulin secretion in studies with healthy subjects/patients with
type 2 diabetes; antibody interference and overlap with
therapeutic insulin in patients with type 1 diabetes; subcutaneous
absorption erratic and reduces power for similarity
Pharmacodynamic
comparability
Similarity of glucose clamp metrics such as
time of onset, peak, shape and duration of
profile, area under concentration curve
Similarity of glucose clamp metrics such as time of onset, peak,
shape and duration of profile, area under glucose infusion curve;
different metrics (e.g. peak or 24-h) important for different
insulin types; poor power for demonstrating clinical similarity;
interpretation of long glucose clamps problematic
Clinical efficacy Key metrics (e.g. peak postprandial or
fasting glucose) comparable; HbA1c and
hypoglycaemia comparable.
HbA1c poor discriminator; hypoglycaemia not very sensitive;
SMPG measures required careful quality control.
Clinical safety Similar adverse and serious adverse event
profiles
Numbers studied far too small and short to detect uncommon
novel side effects; doubts about the ability to detect such events
with conventional pharmacovigilance approaches/Risk
Management Plans
Immunogenicity Insulin antibody profiles including cross
reacting and neutralizing
Mainly a surrogate for purity of insulin derivatives; insulin antibody
assays methods not well standardized; non-specific activity
confounds interpretation
Devices Precision and ease of use data;
interchangeability of cartridges/devices
Limited information available; accessible to independent studies
EPAR, European Product Assessment Report; EU, European Union; HbA1c, glycated haemoglobin; SMPG, self-monitored plasma glucose.
physician prescribing. In the EU, price discounts of up to 35%
have been realized from such substitutions outside of diabetes
care [7]. In the USA, savings of ∼$25 billion in expenditures
for biologicals are anticipated from the introduction of bio-
similar medicines between 2009 and 2018 [8]; however, it is not
yet clear whether the potential for lower prices will be realized
with biosimilar insulins. Highmanufacturing and development
costs mean that price reductions will be much less than those
experienced for generic drugs.
Regulatory Issues
The production techniques used by manufacturers of bio-
similar insulins may be very different from those used for
the original products; for example, in using yeast rather than
bacteria. To be considered the same product, a biosimilar
insulin must have the same primary structure (amino acid
sequence) as the original version, but it may differ in other
molecular characteristics, such as protein folding and gly-
cosylation [4]. While there is no scientific definition of two
such products being identical through evaluation of their
chemical/analytical properties, their metabolic effects, their
pharmacokinetic/pharmacodynamic properties and their clin-
ical characteristics in randomized controlled trials, a decision
can be made that they are clinically similar. For regulatory
approval, manufacturers must provide data for their insulin
copy in the areas mentioned and commit to post-marketing
surveillance; however, the regulatory approach is not uniform
[3], and at present there is no consensus on what constitutes ‘no
meaningful clinical difference’. Below we review the domains
of evidence that contribute to such an assessment.
Manufacturing and Batch-to-batch Variability
Little information is available to the clinician about the
manufacturing process of insulins (and biosimilar insulins),
and essentially none about its quality. This is relevant because
the required expertise for quality insulin manufacture is such
that until recently it has been restricted to a small number of
companies in the market for 80 years or more. The process
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of manufacture does differ markedly between companies in
some cases, with Novo Nordisk and Biocon using a different
yeast as the primary fermentation organism, while Sanofi and
Eli Lilly use Escherichia coli-based systems [9]. Yeasts but not
bacteria may lead to glycosylated proteins [10]. Fermentation is
followed by different chemical processing of the fermentation
product, attributable in part to different promoters and A/B
chain linkers and then different purification steps.
The information on how manufacturers have to demon-
strate to the regulators that they will maintain adequate
batch-to-batch quality, and how they monitor it, is not in the
public domain in any useful detail, and thus not available for
independent assessment. There has been an anecdotal report
from India about poor-quality insulin batches (subsequently
withdrawn) being marketed by a local manufacturer [11]. This
highlights the fact that biosimilar medicines are not manu-
factured in a continuous process but in batches, determined
by fermentation tank size. As the subsequent separation and
purification techniques are complex, all biologicals are subject
to inherent variability in quality. In addition, therapeutic
proteins are unstable, a particular problem with insulin. As a
result there are major challenges to maintaining the necessary
batch-to-batch quality standards.
The issue then is that while results of continued internal
monitoring of manufacturing processes are not made public,
the guarantee of continuing biosimilarity is dependent on
this monitoring. Problems in this area may be the basis of
the clinical observations from Mexico and India that some
copies of insulin glargine appear to have a dissimilar glycaemic
effect [10,11]. As information on batch quality is not in the
public domain, clinicians and users are forced to rely on any
company maintaining a reputation for only bringing to market
batches that meet stringent quality requirements. This requires
that companies have in turn implemented a quality assurance
system that can act truly independently from economic con-
siderations. Even so, some aspects, such as immunological
responses, could vary from batch-to-batch dependent on
purity and stability. For insulin, to our knowledge, this is not
monitored by anyone.
It is evident then, that as more biosimilar insulins come to
market, independent studies of batch-to-batch variability, and
if possible clinical correlates, are desirable [10,12].
Preclinical Studies
Insulin, or for insulin glargine one of its metabolites, exerts
its actions through the insulin receptors and, following acti-
vation of these, through intracellular biochemical pathways.
A biosimilar insulin should then bind to, and dissociate from,
the two main types of insulin receptor, and the insulin-like
growth factor-1 (IGF-1) receptor, to the same measurable
extent as the original insulin. The dissociation rate is thought
to be important because the post-receptor signalling path-
ways of insulin include metabolic and growth promotional
pathways, and a historical rapid-acting insulin analogue
(B10-Asp-human-insulin) is believed to have manifested its
tumorigenic activity as a result of slow dissociation from
its receptor [13]. Assessment of both receptor binding and
post-receptor activity is further complicated because a range
of tissues and cell lines have been used for preclinical studies
with different insulins, often with limited clarity as to their
pathophysiological relevance. As well as the type of assay, the
quality with which these are performed is relevant.
Nevertheless, similar binding and activity ought to be mea-
surable in whatever cellular models are used. It is interesting to
note therefore, that this was not the case for the Lilly insulin
glargine studies, where the EMA Assessment Report (public
domain version) discusses increased binding to both insulin
receptor types compared with original glargine, increased
lipogenic activity in adipocytes, and increased mitogenic activ-
ity in transformed osteosarcoma cells (perhaps mediated by
the IGF-1 receptor), and these increases were of the nominally
important orders of 20–60% [2]. The assays appear to be poor
discriminators, however, and as these findings were below a
company-defined ‘minimum significant ratio’, they did not
establish difference despite statistical significance in some
cases, nor it seems did they establish biosimilarity. A conclu-
sion might be that these methods are inherently unsuitable for
these purposes. Indeed, the models failed by a large margin
(±70%) to confirm similarity of two of the company’s own
formulations of insulin glargine from different manufacturing
sources for mitogenic effects on hepatoma cells.
Rat pharmacokinetic data are also briefly reported in the
Abasaglar European Product Assessment Report (EPAR) [2];
however, the insulin assay was noted to be ‘extremely variable’,
and without correction for rat endogenous insulin secretion,
and seems unlikely to have any power to contribute evidence
of biosimilarity [2]. As is usual with insulin, repeated dose
toxicology studies were associated with a high death rate in
the animals (attributed to hypoglycaemia), and again can be
regarded as non-contributory [2].
It appears then that these tissue and small animal studies
were non-contributory to establishing biosimilarity. If this is
the case, then it seems clinicians and consumer champions
(advocates) will be able to largely ignore such studies for future
biosimilar insulins, even if, as in this case, they are specified by
the regulators [3].
Human Pharmacokinetic and Pharmacodynamic
Studies
Similar pharmacokinetic and pharmacodynamic profiles are
suggested by the EMA as the mainstay of proof of similar effi-
cacy of an insulin copy and the original insulin [14]. It is also
a core component of most other biosimilar guidelines, whether
general or specific for insulin [3]. This makes sense, in partic-
ular for insulins, where the shape of the time–concentration
profile and time–action profile after subcutaneous injection is a
critical part of the clinical specification of any one preparation,
unlike most biopharmaceuticals. Accordingly, the EMA goes
into some detail on the conduct of the cross-over, double-blind
euglycaemic glucose clamp studies using suitable single sub-
cutaneous doses [14]. Clinicians will want to know that such
studies have been performed to these standards, implying full
publication in peer-reviewed journals.
What constitutes a clinically significant difference in
glucose-lowering efficacy between two insulins?Most clinicians
Volume 17 No. 10 October 2015 doi:10.1111/dom.12491 913
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would probably respond with a figure of ±10% or less, based
on the clinical responses of people with diabetes to changes
in insulin dose. Some guidance is available in the standard
which has been set for pen-injectors, of ±5% (for a ≥20 unit
dose) [15]. While pharmacopoeias would allow similar ranges
for differences between batches of insulin vials, most quality
insulin manufacturers aim for closer to ±1% based on confir-
matory protein content assays and high-performance liquid
chromatography; thus, the EU requirement of a confidence
interval (CI) of−20 to+25% of the ratio of certain major phar-
macokinetic parameters seems to be rather wide for allowing a
conclusion to be drawn on clinical biosimilarity. Although such
limits are not specifically set for pharmacodynamic measures,
it would not be expected that clamp glucose requirements
for such parameters would be tighter than for insulin assay
measurements.
Again, data are now available from the Lilly insulin glargine
clamp studies [16–18]. These appear to be of good quality,
and the mean pharmacokinetic and pharmacodynamic curves
are essentially superimposable. It is clear, however, that the
precision of clamp studies in people without diabetes (even
with a reasonable sample size of 46–48 people) only gives CIs
of around ±15–20% difference from unity, and then only for
grosser measures such as 24-h area under the curve and max-
imum concentration/glucose-lowering activity, but consistent
with the EU recommendations. It will probably be unrea-
sonable to expect future clamp studies with other biosimilar
insulins to do any better than this, but clearly no one of these
measurements by itself establishes biosimilarity in terms of
the required clinical accuracy. The Lilly glargine studies are
available in people without diabetes, where the confounder
can be endogenous insulin secretion, and in people with type
1 diabetes, where the confounders are more erratic effects and
the difficulties associated with the transfer from previously
administered insulins without causing metabolic decompensa-
tion [19]. It might be thought that the performance of glucose
clamps in different populations and with different measures
within each study could provide additional reassurance, as the
probability of similarity will clearly increase with each further
study that shows no difference. To some extent this is true, and
as a result, the Lilly data taken together give a high probability
of biosimilarity.
However, some other clamp measures are also pertinent.
Clearly what matters for a long-acting insulin is duration of
effect (ideally exceeding 24 h) at normal insulin doses, and
the peak to 24-h insulin ratio (concentration and action). The
insulin concentrations (including those of the metabolites of
insulin glargine, i.e. M1 and M2) can be surprisingly difficult
to assess, as concentrations will be low at 24 h after a sin-
gle injection. Furthermore glucose-lowering action at 24 h is
affected by the prolonged fast, and thus is spuriously elevated.
One logical approach from a clinical point of view would be
to start the clamp 16 h after a morning injection and a nor-
mal day’s eating, but this seems never to be performed. Equally,
one might expect the biosimilarity of meal-time insulins to be
characterized by lag time of onset after subcutaneous injec-
tion, rate of rise of insulin concentration (and effect), and
rate of fall back to baseline, but such criteria are difficult
to specify, and in practice clinicians will need to use visual
inspection of profiles to assure themselves of similar pharma-
cokinetic/pharmacodynamic profiles.
Lastly, plasma insulin measurements in people with type 1
diabetes can be problematic because of insulin antibodies (and
hence antibody-bound insulin) confounding radioimmunoas-
says. This may account for the erratic pharmacokinetic profiles
seen in the Lilly study in people with type 1 diabetes – so
erratic that they do not contribute to any assessment of
biosimilarity [18].
Clinical Efficacy Studies
Clinicians will judge clinical efficacy by overall blood glu-
cose control [glycated haemoglobin (HbA1c)] measures taken
from self-monitored plasma glucose (SMPG) profiles (includ-
ing prebreakfast for long-acting insulins and postprandial for
meal-time insulins), and hypoglycaemia. In contrast, regula-
tors seemingly believe that HbA1c is the only validated mea-
sure, are suspicious of SMPG measurements (particularly in
open-label studies), and consider hypoglycaemia a safety issue
rather than an efficacy measurement. Indeed, some regulators
[including the US Food and Drug Administration (FDA)] still
regard clinical laboratory-measured fasting glucose as useful,
despite its irrelevance to clinical practice and major underlying
difficulties. It was the insensitivity of HbA1c in showing sta-
tistically significant and clinically relevant difference between
insulin types, as demonstrated by a plethora of studies of new
insulins in the last 15 years, that led the EMA to choose to place
little reliance on clinical studies with HbA1c measurements for
assessment of biosimilarity [14].
Clinicians will want to look at blood glucose profiles, in par-
ticular, prebreakfast levels in ambulatory care for long-acting
insulins, and postprandial andmeal study results for meal-time
insulins, before concluding that biosimilarity is established.
Additionally they will want to consider hypoglycaemia, and
particularly night-time hypoglycaemia for long-acting insulins,
and the risk of late postprandial hypoglycaemia for meal-time
insulins. None of these measures, however, is without its
problem. Glucose control, for example, is highly erratic, fast-
ing glucose levels within individuals having a coefficient of
variation of ∼35% [20]. This is partly mitigated by clinical
studies being generally large, generating statistical power
to show differences. In the Lilly ELEMENT-1 clinical study
in people with type 1 diabetes (n= 545) comparing insulin
glargine and Lantus, mean differences in fasting SMPG at 26
and 52weeks were <0.25mmol/l between the two glargine
insulins, with standard errors (also <0.25mmol/l) suggesting
CIs for a difference of less than ±0.5mmol/l [21].
A similar issue pertains to hypoglycaemia; CIs for both
the proportion of people affected and rates of hypoglycaemia
(events per person-year) are wide for differences between
insulins [22,23]. In ELEMENT-1 the European EPAR recorded
2301 events in 222 people with the Lilly insulin glargine, com-
pared with 2347 events in 216 patients on Lantus. This is
impressive concordance but, given the usual variance of hypo-
glycaemia in randomized controlled trials, is unlikely to be
reproduced in future biosimilar studies for reasons of chance.
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Accordingly, as with the glucose clamp data, clinicianswill need
to consider glucose measurements and hypoglycaemia in the
totality of clinical data when assessing biosimilarity.
Immunological Aspects
Subcutaneous administration of insulin can induce formation
of antibodies, as is the case with other peptides. Immunogenic-
ity of a protein is driven by a number of factors, such as the
structural properties of the molecule (primary, secondary and
tertiary structure), glycosylation, contaminants and impurities
from initial production or downstream processing, formu-
lation, dosage, length of treatment and route of application
[24]. The formation of neutralizing insulin antibodies giving
rise to higher insulin doses was a clinically relevant topic
some decades ago, but has not been a problem since highly
purified insulin formulations were introduced, even in the
era of animal insulins. Historically, antibodies generated after
administration of exogenous insulin were speculatively con-
sidered as detrimental to patients in other ways, including
effects on remaining islet 𝛽-cell function and on vascular com-
plications, but this has not been generally accepted for some
while [25].
Interest in insulin antibodies in the context of biosimilars is
relevant in two ways to diabetes care. Firstly, clinically relevant
issues have been observed with other therapeutic peptides,
notably with epoetins, where it is believed that antibody for-
mation resulting from a change in manufacturing process
led to pure red cell aplasia and the resulting deaths [26]. For
insulin, the long experience with impure insulins from the
1920s might seem to make such an experience unlikely, but
bioengineering does give rise to the possibility of novel insulin
derivatives. While it is likely that these would be removed by
the purification processes used, and if they were not removed
the most likely adverse reaction would be antibody-mediated
insulin resistance, this remains a background concern. Insulin
antibodies may possibly be involved in the pathogenesis of
diabetes, through priming of the islet 𝛽-cell as a target, and it is
not known if novel antibodies formed in response to exogenous
insulin could contribute to acceleration of islet 𝛽-cell decline
in the early time period after diagnosis of type 1 diabetes [27].
Secondly, low levels of insulin antibodies can be used as a
surrogatemarker of impurities arising through inadequate pro-
duction processes.Theremay be asmany as 30 steps in theman-
ufacture of a modern insulin analogue. Some of these steps are
associated with by-products, and others are designed to remove
them [9]. Conventional techniques cannot always pick up faults
in the production process, a well-documented example being
the thio-ester problem with biosimilar growth hormone [28];
therefore, in all guidelines for approval of biosimilar insulins, at
least some evaluation of the formation of antibodies is included
[3]. These evaluations differ, however, in duration, number
of people exposed and assay methods, and it is unclear what
pre-approval studies are optimal in a situation where only a few
individuals may be particularly at risk. Another issue is that
such studies are only performed pre-approval, and are not used
for continuedmonitoring of manufacturing quality, whichmay
be the real issue [26].
Even in countries with a well-established pharmacovigi-
lance system (see below), it is questionable if an increase in
insulin requirements or insufficient metabolic control induced
by an immunological reactionwill be detected. In practicemost
physicians will simply switch to another insulin formulation
if there is suspicion of such an issue, without any systematic
follow-up.
Interpreting the results of evaluation of immunological
aspects of insulins is not straightforward, as the many method-
ological aspects and approaches need to be understood. In
practice, most clinicians will be forced to follow the decisions
of the regulators and perhaps published opinions from experts,
but the public domain material is likely to be limited to a short
summary in reports of clinical studies. Data on mean insulin
antibody responses are often given in these, but care needs to
be taken with the type of results given, as it is the few individ-
uals adversely affected who are of importance from a clinical
point of view. Even then a problem arises that the original
insulin is often the insulin used by the study participants before
randomization. Their immune systems will have adapted to it
and, in the rare event of a more extreme problem, they would
not be eligible for the study. Somewhat more useful can be
comparative antigenicity. In many instances these are simple
chance phenomena, but they might show differences compared
with the original insulin. More usefully, clinicians should ask
to see comparative numbers of participants reaching clinically
higher levels (in many assays percent binding above 30%),
bearing in mind that neutralizing effects of antibodies to other
therapeutic peptides in diabetes (exenatide) may affect only
1% of the population [29]. In the Lilly ELEMENT-1 study only
1 participant appears for have exceeded 20% binding, and that
was on the original glargine, with no effect on HbA1c [21], but
it may well be that little such information will be put into the
public domain.
Safety
As noted above, preclinical toxicological requirements are
limited for a biosimilar, and animal testing is particularly diffi-
cult to perform for insulin. It might therefore be expected that
clinical studies are important in this regard; however, a 500+
person 1-year study, such as that performed for the Lilly
glargine, has no power to detect a serious adverse event
occurring as often as three times per 1000 people per year.
Accordingly, potential novel safety issues will generally be
untested for insulin copies. Most of the safety data collected in
these studies are valueless background adverse events [30].This
does not mean that we should expect safety issues to show up
with these insulin copies, as insulin is a well-known medi-
cation; however, we should be aware of our limited ability to
detect such issues during the approval process, especially in
the abbreviated process used for documenting biosimilarity
of insulin copies. It is worth noting that we would have even
fewer data about the safety of the Lilly glargine if this had not
undergone an approval process as a new insulin in the USA.
In theory then, clinicians should be looking for good phar-
macovigilance postmarketing studies to unmask potential
safety issues. In the current data environment, however, such
Volume 17 No. 10 October 2015 doi:10.1111/dom.12491 915
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studies too must be regarded as largely unfit for purpose,
and this may become a particular problem if biosimilars are
prescribed and dispensed by approved name, and people with
diabetes switch (of or against their own will) between versions
from different manufacturers. In the EU, legislation does
require that each biosimilar has a distinct brand name [31]. In
some countries, further safety distinctions between biosimilars
and original products may be created. In the UK, for instance,
the Medicines and Healthcare Products Regulatory Agency
requires biosimilars to have a black triangle symbol (safety
reporting alert) on the package, but many countries have no
such measures in place.
Insulin Devices: Pens and Pumps
Manufacturers of biosimilar insulins may develop their own
disposable or reusable insulin pen-injectors, or provide car-
tridges that could be marketed for use in reusable pen-injectors
manufactured by either the original insulin manufacturer
or a third party. Any new pen-injector will have to meet
normal quality standards; for example, 5% precision down
to a 20-units injection, and ±1 units below this [15]. Some
current pen-injectors are likely to perform better than this,
and it may be that manufacturers will now be motivated to
publish that information in an attempt to persuade clinicians of
advantages in clinical performance, particularly at lower doses
[32,33]. Compatibility of cartridges with existing and third
party pen-injectors is likely to be a requirement of regulatory
approval.
Other quality issues are design issues such as prevention
of injection of a last dose for which the cartridge does not
have remaining capacity, readability of dial-up, and pressure of
injection button. Clinicians should ask for such data for novel
pen-injectors.
For insulin pumps, data on insulin stability in usewill need to
be provided to regulators, including reassurance that infusion
set occlusion will not become any more of a problem than with
the original insulin. Such issues are also affected by the excip-
ients used in formulations [34]. Normally these issues will be
covered by a comment in the label/summary of product charac-
teristics to the effect that pumpuse is appropriate.Without such
comment, clinicians might judge that such use is undesirable.
Interchangeability and Substitution
There is a clear distinction between biosimilarity and inter-
changeability; confirmation of biosimilarity does not imply
interchangeability. A perfectly interchangeable product may be
substituted by a pharmacist, without intervention or even nec-
essarily notification of the prescribing clinician [3]. A biosimi-
lar productmay yield a similar efficacy, tolerability and safety to
the original, but a switch between these products may require
input from a clinician. Substitution is a process, whereas inter-
changeability is a regulated property of a biosimilar in a partic-
ular clinical scenario.
Clinicians prescribing insulin typically avoid switching
patients from one insulin formulation to another without
good reason. This is based on their practical experience that,
for a given individual coverage of prandial or basal insulin,
requirementsmight workwell with a given formulation, but not
with a nominally very similar insulin (e.g. anotherNPH insulin,
or another rapid-acting analogue). Often, after taking time to
optimize an insulin regimen, a person with type 1 diabetes has
around two confirmed hypoglycaemic excursions a week, and
a serious event yearly. People often develop a love–hate psycho-
logical relationship with their insulin, knowingly dependent on
it but with a fear of instability. A proportion of people whose
regimens are changed become convinced (perhaps correctly),
therefore, that this has caused marked deterioration of glu-
cose control, resulting in deterioration in quality of life and
increased medical input, sometimes long term. Any decision
to change is therefore not taken lightly, and neither the treating
physician nor the user is usually willing to switch to a different
insulin formulation without good reason. A designation of
interchangeability (guarantee that insulin action is more or less
identical, not just similar, to the original insulin) may however
make clinicians’ views on such changes more positive.
In the EU, decisions on interchangeability and substitution
of biosimilars with original products are not within the remit
of the EMA, and interchangeability studies are not part of the
regulatory requirements [14,31]. Decisions on interchangeabil-
ity and/or substitution rely on national authorities that have
access to the scientific evaluation performed by the EMA and
all submitted data, and use other expert opinion. European
countries thus vary over substitution guidance. In the USA, the
FDA has recently published a list of licensed biological prod-
ucts and interchangeable biosimilars [35]. The agency has des-
ignated a four-part standard for biosimilar interchangeability:
not similar; similar; highly similar; and highly similar with a
fingerprint-like similarity [35]. Interchangeability of biosimilar
insulins is, however, not currently considered under this stan-
dard in the USA, and each state in the USA can decide for itself
about how substitution will be handled.
Summary and Conclusions
With the availability of first published data on the properties of
a biosimilar long-acting insulin, and with some data on copies
of insulin in other countries, it is now possible to assess what
will be meant by ‘similarity’, and what the issues surround-
ing such an assessment are. Furthermore, the issues around
immunogenicity for biosimilar insulins are becoming clearer.
The release of data on the Lilly insulin glargine approval in
the EU shows the complexity of biosimilar approval, and is
for the more general understanding of such assessments for
the future. It appears as if the experts at the EMA have done
a thorough job in evaluating the Lilly insulin glargine [2]. For
clinicians and insulin users (and their champions), however,
the situation is not easy. In some areas, such as manufacturing
process and quality, reliance must be placed on the regulators,
but there is no opportunity to monitor their performance as
nothing in this area appears in the public domain. So there
may be differences in the quality of the evaluation process
(if any is in place) between regulatory authorities around the
globe. For batch-to-batch variability (even in already marketed
insulins!) the concern is that all such monitoring is performed
and retained by manufacturers.
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From the published and presented data on the Lilly insulin
glargine it is clear that no one domain of information, including
pharmacokinetic and pharmacodynamic studies in humans, is
able to provide an assurance of biosimilarity. Indeed, the con-
tribution of preclinical studies as conducted by/for Lilly and
reported in the European EPAR appears limited [2]. The glu-
cose clamp studies are clearly contributory but only if all the
evidence frompharmacokinetic and pharmacodynamic studies
is taken together, including studies from people without dia-
betes and people with type 1 diabetes, and uses measures above
and beyond those prioritized by the EMA, and visual inspection
of the profiles. Some knowledge of the limitations of glucose
clamps, particularly clamps of ≥24 h, is needed if findings are
not to be misinterpreted. Because of this, clinical studies are
clearly needed, notably to address specific questions such as
comparability of attained prebreakfast glucose concentrations
and of nocturnal hypoglycaemia; however, here the precision is
not good enough to give assurance within a clinically meaning-
ful ±5%, unless all the evidence is assessed together.
Safety may not seem a big issue given the long history of
insulin usage from diverse sources, but we are concerned
that the same was believed to be true for epoetin and growth
hormone; safety issues are often a case of ‘hands up anyone
who is not here’. Presently none of the preclinical, clinical or
immunological assessments seems capable of dealing with
that potential risk. Pharmacovigilance postmarketing is the
traditional but rather flawed way of dealing with such risks
and can only work here if prescribing is based on proprietary
not approved names. Widespread substitution may destroy
the chances of detecting such safety risks; in some countries
in South America, patients/physicians are required to use
whatever insulin was purchased by the Ministry of Health in a
bidding process. Switches might be necessary as often as every
6months.
Accordingly, we see the need for longer-term clinical studies
(or at least formal registries), studies addressing batch-to-batch
variability for both original and biosimilar insulins, studies
of delivery devices, and interchangeability in practice, as
well as comprehensive pharmacovigilance and postmarketing
surveillance. Of course more extensive clinical evaluations of
the efficacy and safety of new biosimilar insulins raise the risk
of negating the price advantage of a slimmer development pro-
gramme, and it is not our intention to protect the established
insulin manufacturer and keep potential new manufacturers
from entering the market.
It is also not our aim to raise mistrust against such products,
but to establish a sound and rational approach with biosimilar
insulins. We believe that the issue is sufficiently important to
people with diabetes to be adopted and kept under review by
the major diabetes associations, nationally and internationally.
The database is also now mature enough for organizations
such as the World Health Organization to extend advice on
biosimilar products to address regulation of biosimilar insulins
specifically, rather than just generally as at present [3].
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